DeciBio Consulting Acquires Emmes Group's Molecular Diagnostics and Oncology Databases to Expand Precision Medicine Intelligence Platform

On September 23, 2019, VCBeat (WeChat ID: vcbeat) learned from foreign media reports that DeciBio Consulting (DeciBio), a strategic consulting and market intelligence firm focused on precision medicine, announced the acquisition of ownership of Emmes’ Molecular Diagnostics (MDx) Infectious Disease Database and Oncology Database. The transaction became effective on January 1, 2020.

DeciBio aims to strengthen and expand the solutions offered to customers through this acquisition. Upon completion of the transaction, DeciBio will take over the development, sales, and marketing activities of Emmes’ database products, while the Emmes Group will provide support to DeciBio in data collection.

The Emmes MDx (ID) database has become the sole and essential source of data for in-depth customer-level metrics, drawing on information from molecular diagnostic tests conducted by more than 1,000 MDx testing laboratories across the United States. Manufacturers leverage the Emmes MDx (ID) database to support the following business functions: in sales, analyzing and prioritizing customers; in strategic marketing, assessing changes in market share among instrument and assay manufacturers and evaluating the utility of new testing methods; and in business development, identifying winners and losers by customer type and understanding competitive dynamics.

The Emmes Oncology Database provides similar client-level information, focusing on tissue-based testing from 300 anatomical pathology, molecular oncology, and genetics laboratories in the United States.

“Integrating the Emmes database into DeciBio’s market intelligence portfolio is an exciting development for us,” said David Cavanaugh, Founding Partner at DeciBio. “We have witnessed firsthand and experienced the reliability of these databases in understanding and evaluating user-level operational and decision-making aspects of molecular diagnostic testing.”

Edward Weiner, Founder and President of the Emmes Group, stated, “DeciBio has become an ideal partner for its clients by leveraging its specialized expertise, exceptional skills, and unwavering commitment to client needs and high-quality service. I am confident that, driven by DeciBio’s team spirit and robust resources, they will operate the Emmes database more effectively and create greater value for our clients.”

DeciBio is a strategic consulting and market intelligence firm focused on precision medicine. DeciBio provides consulting services including growth planning, market and opportunity assessment, product and portfolio strategy, and corporate due diligence. The company also offers market intelligence products, including data visualization and analytics platforms, as well as reports related to immuno-oncology, liquid biopsy, and cancer biomarkers.

Emmes is an information and knowledge provider whose core competency lies in designing and implementing surveys based on proprietary research. The company focuses on capturing critical market facts, judgments, preferences, and perceptions, and transforming this information into actionable insights. Its business activities are primarily concentrated in the healthcare sector, particularly in diagnostics and laboratory instrumentation.

(Compiled by Tian Shuhang)